Improved surface functionalisation for biosensor based analytics of membrane proteins

Herceptin, also known as Trastuzumab, is a pioneering antibody drug used in the treatment of HER2-positive breast cancer. By targeting the HER2 protein abundantly expressed on the surface of certain breast cancer cells, Herceptin serves as a beacon, marking these cells for immune system recognition and subsequent destruction. This mechanism highlights the significance of membrane proteins as drug targets not only for Herceptin but also for numerous other therapeutics under development or already in use.

In the realm of drug development, evaluating candidate molecules is pivotal, with a crucial test being the assessment of their binding affinity and kinetics. However, the inherent instability of many membrane proteins outside of their native cellular environment poses a significant challenge. Current methods for analysing binding affinity and kinetics typically require the isolation of proteins, leading to bottlenecks in therapeutic development.

Alternative approaches, such as extracting and stabilizing membrane proteins, are time-consuming and complex.

To address these challenges, our project aims to adapt our existing Amperia antibody quantification system for the new application of measuring the binding affinity and kinetics of antibodies with membrane proteins. The system will seamlessly integrate with intact cells, leveraging the Redox Electrochemical Detection (RED) platform technology pioneered by HexagonFab. Through this project, we will develop the optimal sensor coating to facilitate experiments that involve whole cells.

The optimal production and storage conditions for achieving the ideal surface functionalization must be identified. This includes testing of various production methods followed by precise chemical analysis to evaluate the properties of the surface functionalization. In collaboration with NPL, this project aims to evaluate the influence of different production processes on the surface functionalization.

By identifying the most effective process conditions, HexagonFab can enhance the performance of its sensors and ensure the successful development of advanced technologies.

Understanding and optimizing the surface coating process for cell assay applications will ensure that the sensors exhibit the required sensitivity and specificity. By facilitating cheaper and faster development pathways for innovative therapeutics, this technology promises to benefit patients and enhance the healthcare ecosystem.